Chronic constipation
Conditions
Interventions
None listed
Sponsors
Nishi-Shinjyuku Kisaragi Clinic.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients 20 years or older (2) Patients diagnosed with chronic constipation who have observation data on the urge for bowel movement from before to 2 weeks after starting treatment by elobixibat (3) Patients who were administered elobixibat for at least 2 weeks continuously between April 19, 2018 and October 31, 2020 (Concomitant use of other drugs for the treatment of constipation should be allowed)
Exclusion criteria
Exclusion criteria: (1) Patients with a history of hypersensitivity to elobixibat (2) Patients with confirmed or suspected bowel obstruction due to a tumor or hernia (3) Patients with suspected constipation due to organic disease (4) Patients who participated in a clinical trial or interventional study during the study period (5) Patients who have been determined by a physician to be inappropriate to administer elobixibat
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the urge for bowel movement before and after 2 weeks of treatment by elobixibat | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the urge for bowel movement before and after 6 and 10 weeks of treatment by elobixibat Satisfaction with treatment after 2, 6, and 10 weeks of treatment by elobixibat Bowel urgency after 2, 6, and 10 weeks of treatment by elobixibat Time from intake of elobixibat to urge for bowel movement after 2, 6, and 10 weeks of treatment by elobixibat Comparison of stool frequency before and after 2, 6, and 10 weeks of treatment by elobixibat Comparison of stool type on the Bristol Stool Scale before and after 2, 6, and 10 weeks of treatment by elobixibat Improvement of abdominal bloating after 2, 6, and 10 weeks of treatment by elobixibat Improvement of abdominal pain after 2, 6, and 10 weeks of treatment by elobixibat Discontinuation rate of stimulative laxatives after 2, 6, and 10 weeks of treatment by elobixibat Use of concomitant drugs for constipation Sub-analysis by the patients' background and the treatment status of elobixibat Incidence rate and item of adverse events and adverse drug reaction Discontinuation rate of elobixibat | — |
Countries
Japan
Contacts
Public ContactTakayuki Ishikawa
Nishi-Shinjyuku Kisaragi Clinic. Internal medicine, Gastroenterology
Outcome results
None listed